See more : Woori Technology Investment Co., Ltd (041190.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Li Kang Biomedical Co., Ltd. (6242.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Li Kang Biomedical Co., Ltd., a leading company in the None industry within the None sector.
You may be interested
- Impex Ferro Tech Limited (IMPEXFERRO.BO) Income Statement Analysis – Financial Results
- Capitala Finance Corp. (CPTAG) Income Statement Analysis – Financial Results
- Mega Union Technology Inc. (6944.TWO) Income Statement Analysis – Financial Results
- Seihyo Co., Ltd. (2872.T) Income Statement Analysis – Financial Results
- Chongqing road & bridge co.,ltd (600106.SS) Income Statement Analysis – Financial Results
Li Kang Biomedical Co., Ltd. (6242.TWO)
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 629.38M | 684.25M | 386.97M | 456.72M | 0.00 |
| Cost of Revenue | 203.23M | 295.68M | 122.29M | 156.09M | 0.00 |
| Gross Profit | 426.15M | 388.58M | 264.68M | 300.64M | 0.00 |
| Gross Profit Ratio | 67.71% | 56.79% | 68.40% | 65.82% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K |
| General & Administrative | 46.74M | 42.77M | 37.49M | 39.59M | 0.00 |
| Selling & Marketing | 246.03M | 208.45M | 169.95M | 180.12M | 0.00 |
| SG&A | 292.77M | 251.22M | 207.44M | 219.71M | 0.00 |
| Other Expenses | 0.00 | 2.18M | 5.49M | 5.36M | 0.00 |
| Operating Expenses | 292.77M | 251.22M | 207.44M | 219.70M | 0.00 |
| Cost & Expenses | 496.01M | 546.89M | 329.72M | 375.78M | 0.00 |
| Interest Income | 3.27M | 1.55M | 1.20M | 1.19M | 1.24M |
| Interest Expense | 618.00K | 290.00K | 455.00K | 546.00K | 779.00K |
| Depreciation & Amortization | 11.74M | 10.99M | 12.89M | 15.02M | 0.00 |
| EBITDA | 151.37M | 152.07M | 76.83M | 102.51M | 106.08M |
| EBITDA Ratio | 24.05% | 22.22% | 19.85% | 22.44% | 0.00% |
| Operating Income | 133.37M | 141.09M | 63.94M | 87.49M | 0.00 |
| Operating Income Ratio | 21.19% | 20.62% | 16.52% | 19.16% | 0.00% |
| Total Other Income/Expenses | 5.77M | 3.44M | 6.24M | 6.00M | 3.03M |
| Income Before Tax | 139.14M | 140.80M | 63.48M | 86.94M | 0.00 |
| Income Before Tax Ratio | 22.11% | 20.58% | 16.40% | 19.04% | 0.00% |
| Income Tax Expense | 28.15M | 28.70M | 12.05M | 17.68M | 0.00 |
| Net Income | 110.99M | 112.09M | 51.44M | 69.27M | 0.00 |
| Net Income Ratio | 17.64% | 16.38% | 13.29% | 15.17% | 0.00% |
| EPS | 4.14 | 4.18 | 1.86 | 2.50 | 0.00 |
| EPS Diluted | 4.12 | 4.16 | 1.85 | 2.48 | 0.00 |
| Weighted Avg Shares Out | 26.81M | 27.73M | 27.72M | 27.72M | 27.72M |
| Weighted Avg Shares Out (Dil) | 26.96M | 27.88M | 27.85M | 27.92M | 27.92M |
No news found for: 6242.TWO
Source: https://incomestatements.info
Category: Stock Reports